BaiKai Pharma Announces First Patient Dosed in Phase I Clinical Trial of Novel ADC BIO-106

On May 16, 2022 (U.S. time), the first patient was dosed in the Phase I clinical trial of BIO-106, an innovative antibody-drug conjugate (ADC) independently developed by Baikai Biopharma with full international intellectual property rights.

BIO-106 is a novel antibody-drug conjugate (ADC) targeting solid tumors with high TROP-2 expression. Leveraging Baikai Biopharma’s proprietary payload technology, BIO-106 incorporates molecular design optimizations to minimize damage to normal tissues, thereby offering an improved therapeutic window and favorable safety profile. BIO-106 holds promise for demonstrating efficacy across a range of tumor types.

Dr. Robert Sikorski, CMO of Baikai Biomedicalstated, “Our team is thrilled to bring a novel TROP2-targeted ADC product to patients with advanced solid tumors. We hope that the unique design features of BIO-106 will deliver superior therapeutic outcomes compared to existing treatment options.” World-leading cancer centers will also participate in this Phase I clinical trial.

Hangzhou Baikai Biomedical Co., Ltd. is a high-tech pharmaceutical company dedicated to the innovation, research, and development of novel anti-tumor drugs. Founded by overseas experts, Baikai Biomedical’s core R&D team comprises scientists who have held senior research and development positions at renowned multinational biopharmaceutical companies or research institutions, bringing with them extensive successful experience in new drug development. The team members span various disciplines within drug development, covering all key aspects of the process. Our mission is to provide cancer patients with best-in-class, first-in-class anti-tumor therapies, enabling more effective treatment of cancer.